Australian researchers have discovered that men with incurable prostate cancer, but without symptoms, who received immediate hormone treatment on the TROG 03.06 (TOAD) clinical trial, had an increase in survival over those who delayed treatment – with 80% still alive after six years, compared to 65% of men for whom treatment was delayed until they…
For the first time, a large randomized trial has suggested that overall survival is improved by the addition of adjuvant chemotherapy to androgen suppression and radiotherapy in men with localized, high-risk, hormone-sensitive prostate cancer. Docetaxel has been used to treat metastatic hormone-resistant prostate cancer for a number of years, and this new study—RTOG 0521—suggests that…
Too many men are getting the all-clear for prostate cancer when in fact they have the disease, say doctors, who are calling for an overhaul of testing techniques. Professor Stephen Langley, a prostate cancer expert, blames the misdiagnoses on inaccurate biopsies. Under current guidelines from NICE (National Institute for Health and Care Excellence), men with…
A central challenge in diagnosing and treating prostate cancer is distinguishing fast from slow, aggressive from indolent. Consider the experience of Gerald Alexander. A former Air Force surgical service specialist who completed several tours of duty in Iraq and Afghanistan, Alexander was preparing to retire from the military and make a transition to teaching high…
ROCHESTER, N.Y. — Hans Schmitthenner, a research scientist at Rochester Institute of Technology, hopes to make detecting prostate cancer — the second leading cause of cancer deaths among men — less of a guessing game. Non-cancerous cells as well as cancerous cells can produce elevated PSA levels in the test for prostate-specific antigens commonly used…
Genomic Health, Inc.(GHDX – Analyst Report) recently declared that Medicare contractor, Palmetto GBA, has issued a draft local coverage determination (LCD) for its Oncotype DX prostate cancer test. The draft LCD recommends coverage and reimbursement of the Oncotype DX prostate cancer test for applicable Medicare patients across the U.S. This should encourage the identification of…
International study of advanced prostate cancer genome finds abundance of potential targets for drug therapy The first major effort to canvas the genomic landscape of advanced prostate cancer has revealed that many patients may carry some type of genetic abnormality that can be targeted with existing or potential drugs. The finding, reported today by a…
AdMeTech Foundation Joins Senator Harriette Chandler, Mosaic and Barbershop Health Network to Raise Awareness WORCESTER, MA, May 15, 2015—AdMeTech Foundation will support and participate in the “Saving Our Men Symposium” on Sunday in coordination with Mosaic Cultural Complex, which created Barbershop Health Network to educate men of color about screening and early detection of preventable…
Importance of Baseline Screening in Younger Men is Underscored NEWTON, MA, May 15, 2015—AdMeTech Foundation and the Massachusetts Prostate Cancer Coalition (MPCC) today led the state’s first public discussion of the Clinical Practice Guidelines for Early Detection of Prostate Cancer developed by the National Comprehensive Cancer Network (NCCN). These guidelines were developed by the world-leading…
Univision TV, which has an extensive outreach in the Massachusetts Hispanic community, covered 7th Annual Prostate Cancer Awareness Day, highlighting 40% higher mortality in the Hispanic community in Boston compared to state average and the importance of early detection in saving lives. This coverage featured several event speakers, including Massachusetts Governor Charlie Baker; Felix Arroyo,…